Rapport Therapeutics prices $150 million convertible senior notes offering

Bitget2026/10/28 10:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rapport Therapeutics priced $150 million of 2.25% convertible senior notes due December 1, 2032.
Underwriters have a 30-day option to purchase another $22.5 million of notes to cover over-allotments.
Closing is expected around October 30, 2026, with net proceeds of approximately $145 million excluding the option.
The initial conversion price is approximately $26.775 per share, a 27.5% premium to the concurrent stock offering price.
Proceeds will primarily support RAP-219 clinical trials, other research and development, working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280600PRIMZONEFULLFEED9854967) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rapport Therapeutics prices $150 million convertible senior notes offering

You may also like

Crypto prices